Benefits
Acute infectious diarrhea reduction
Multiple Cochrane systematic reviews and meta-analyses confirm LGG significantly reduces the duration of acute infectious diarrhea in children by approximately 1 day, particularly when started within 48 hours of symptom onset. ESPGHAN guidelines specifically recommend LGG (alongside Saccharomyces boulardii) as the only probiotic strain with sufficient evidence for routine use in pediatric acute gastroenteritis. Doses of 10^10 CFU/day or higher are most effective.
Antibiotic-associated diarrhea prevention
A 2017 Cochrane review of 23 RCTs (3,938 participants) found probiotic supplementation reduced the incidence of antibiotic-associated diarrhea by 51% (RR 0.49). LGG is one of the two strains (with S. boulardii) with the strongest evidence. Effective when given concurrently with antibiotic therapy and continued for 1–2 weeks afterward.
Atopic dermatitis prevention in infants
Maternal supplementation with LGG during pregnancy and lactation, plus infant supplementation, has been shown to reduce the cumulative incidence of atopic dermatitis (eczema) in high-risk children at 2 years by up to 50% in some trials. Effects on respiratory allergies are more variable. Particularly beneficial for infants with family history of atopy.
Immune function and respiratory infection reduction
RCTs demonstrate LGG reduces the incidence and duration of upper respiratory tract infections in children attending daycare and in athletes. A 2019 meta-analysis found probiotics including LGG reduced URI episodes by 23% in adults and reduced antibiotic prescriptions for respiratory illness.
IBS symptom improvement (limited)
Strain-specific 2025 systematic review meta-analyses identify LGG as one of the strains with reproducible benefits for IBS-related abdominal pain and global symptom scores, though effect sizes are modest. Best evidence is in pediatric IBS populations.
Mechanism of action
Strong epithelial adherence via SpaCBA pili
LGG produces unique SpaCBA pili (mucus-binding pili) that allow exceptional adhesion to human intestinal mucus and epithelial cells. This adhesion enables LGG to outcompete pathogenic bacteria for binding sites and colonize the gut more effectively than most other strains.
Bacteriocin production and pathogen exclusion
LGG produces antimicrobial peptides (microcin-like bacteriocins) that inhibit growth of enteric pathogens including E. coli, Salmonella, Clostridioides difficile, and Helicobacter pylori. Combined with lactic acid production lowering luminal pH, this creates a hostile environment for pathogens.
p40 protein-mediated epithelial protection
LGG secretes a unique soluble protein called p40 that activates EGFR (epidermal growth factor receptor) signaling in intestinal epithelial cells, preventing apoptosis induced by inflammatory cytokines and promoting tight junction integrity. This is a strain-specific mechanism not shared by most other Lactobacilli.
Toll-like receptor signaling and immune modulation
Cell wall components (peptidoglycan, lipoteichoic acid) and exopolysaccharides interact with TLR2/TLR4 on dendritic cells and intestinal epithelial cells, inducing regulatory T-cell differentiation and balanced Th1/Th2 responses. This contributes to atopy prevention and immune homeostasis.
Clinical trials
Position paper of ESPGHAN Working Group on Probiotics and Prebiotics synthesizing data from over 50 RCTs evaluating probiotics in pediatric acute gastroenteritis (AGE). (Szajewska et al. 2014, J Pediatr Gastroenterol Nutr)
Pooled across 50+ pediatric AGE RCTs.
LGG (≥10^10 CFU/day for 5-7 days) recommended as effective adjunct to oral rehydration in pediatric AGE — reduces duration by ~24 hours and reduces diarrhea volume. CRITICAL UPDATE: subsequent large definitive trials (Schnadower 2018 NEJM PROGUT, Freedman 2018 NEJM PERC) did NOT confirm LGG benefit in North American pediatric AGE — both trials negative. ESPGHAN may revise recommendations. The LGG/AGE evidence is now contested; pediatric AGE management depends on clinical setting and provider judgment.
2017 Cochrane systematic review and meta-analysis of 23 RCTs (3,938 participants, primarily children but including adults) of probiotics for antibiotic-associated diarrhea prevention. (Goldenberg et al. 2017, Cochrane Database Syst Rev)
Pooled across 23 RCTs.
Probiotic co-administration reduced AAD incidence by ~51% (RR 0.49, 95% CI 0.32-0.74). LGG and S. boulardii had the strongest evidence. Cochrane evidence quality MODERATE. NOTE: 2018 PLACIDE trial (n=2,981 elderly hospitalized adults) NEGATIVE — probiotics did NOT prevent AAD or CDAD in this population. Pediatric evidence stronger than adult; routine prophylaxis NOT universally recommended.
Randomized double-blind placebo-controlled trial of perinatal LGG supplementation. Mothers received LGG for 2-4 weeks before delivery, then either continued or infant received LGG for first 6 months. (Kalliomäki et al. 2003, Lancet)
Pregnant mothers and infants.
Cumulative incidence of atopic dermatitis was 23% in LGG group vs 46% in placebo at age 2 (50% relative reduction). CRITICAL UPDATE: subsequent independent trials (Boyle 2011 PROBAT; Kopp 2008; Soh 2009) have NOT consistently replicated this effect. The Lancet 2003 finding has been contested. Current allergy/atopy prevention guidelines are more cautious about probiotic recommendations.